54 related articles for article (PubMed ID: 20392521)
1. The Role of Co-Signaling Molecules in Psoriasis and Their Implications for Targeted Treatment.
Liu S; Xu J; Wu J
Front Pharmacol; 2021; 12():717042. PubMed ID: 34354596
[TBL] [Abstract][Full Text] [Related]
2.
Tomalka AG; Resto-Garay I; Campbell KS; Popkin DL
Front Immunol; 2018; 9():2552. PubMed ID: 30455699
[TBL] [Abstract][Full Text] [Related]
3. Immunotargeting in the management of psoriasis.
Kaffenberger BH; Kaffenberger TM; Wong HK
Immunotargets Ther; 2013; 2():51-60. PubMed ID: 27471688
[TBL] [Abstract][Full Text] [Related]
4. Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
Zaidi A; Meng Q; Popkin D
Immunotherapy (Los Angel); 2015 Dec; 1(1):. PubMed ID: 27110598
[TBL] [Abstract][Full Text] [Related]
5. Current state of renal transplant immunosuppression: Present and future.
Kalluri HV; Hardinger KL
World J Transplant; 2012 Aug; 2(4):51-68. PubMed ID: 24175197
[TBL] [Abstract][Full Text] [Related]
6. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.
Rath T; Baker K; Dumont JA; Peters RT; Jiang H; Qiao SW; Lencer WI; Pierce GF; Blumberg RS
Crit Rev Biotechnol; 2015 Jun; 35(2):235-54. PubMed ID: 24156398
[TBL] [Abstract][Full Text] [Related]
7. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.
Brezinski EA; Armstrong AW
PLoS One; 2012; 7(4):e33486. PubMed ID: 22509259
[TBL] [Abstract][Full Text] [Related]
8. Clinical update on alefacept: consideration for use in patients with psoriasis.
Gade JN
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
[TBL] [Abstract][Full Text] [Related]
9. Development and use of alefacept to treat psoriasis.
Krueger GG; Callis KP
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S87-97. PubMed ID: 12894131
[TBL] [Abstract][Full Text] [Related]
10. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.
Roberts JL; Ortonne JP; Tan JK; Jaracz E; Frankel E;
J Am Acad Dermatol; 2010 Jun; 62(6):968-78. PubMed ID: 20392521
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
[TBL] [Abstract][Full Text] [Related]
12. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
Perlmutter A; Cather J; Franks B; Jaracz E; Menter A
J Am Acad Dermatol; 2008 Jan; 58(1):116-24. PubMed ID: 17997502
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
[TBL] [Abstract][Full Text] [Related]
14. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.
Gribetz CH; Blum R; Brady C; Cohen S; Lebwohl M
J Am Acad Dermatol; 2005 Jul; 53(1):73-5. PubMed ID: 15965424
[TBL] [Abstract][Full Text] [Related]
15. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis.
Krell J; Nelson C; Spencer L; Miller S
J Am Acad Dermatol; 2008 Apr; 58(4):609-16. PubMed ID: 18262681
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
